{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:20:02Z","timestamp":1789662002873,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI001254"],"award-info":[{"award-number":["AI001254"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HDT Bio"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Sudan virus (SUDV) outbreaks in Uganda in 2022 and 2025 created public health concerns in-country and the entire East African region. There are currently no licensed countermeasures against SUDV. We developed a SUDV vaccine candidate based on a nanocarrier (LION<jats:sup>TM<\/jats:sup>) complexed with an alphavirus-based replicon RNA. Here, we compare the protective efficacy of the LION-SUDV vaccine either encoding the SUDV glycoprotein (GP) alone or in combination with the Ebola virus (EBOV) GP (LION-Combination). A LION-EBOV vaccine which is protective against EBOV was also included to determine the potential for cross-protection against SUDV infection. Single-dose vaccinations were conducted three weeks before challenge with a lethal dose of guinea pig-adapted SUDV using a female guinea pig disease model. We demonstrate 100% survival and protection with the LION-SUDV and the LION-Combination vaccines, while the LION-EBOV vaccine achieved 50% protection. Antigen-specific humoral responses correlate with decreased virus replication and survival. This result warrants further studies in larger animal species to ensure that protective efficacy is maintained with the single-dose LION-SUDV vaccine.<\/jats:p>","DOI":"10.1038\/s41467-025-59560-1","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:53:35Z","timestamp":1746536015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-1966","authenticated-orcid":false,"given":"Kyle L.","family":"O\u2019Donnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-3039","authenticated-orcid":false,"given":"Hanna","family":"Anhalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-6177","authenticated-orcid":false,"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-5529","authenticated-orcid":false,"given":"Nikole L.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4833-0255","authenticated-orcid":false,"given":"Troy","family":"Hinkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Taylor","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara","family":"Hatzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit P.","family":"Khandhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-2648","authenticated-orcid":false,"given":"Logan","family":"Banadyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-2697","authenticated-orcid":false,"given":"Jesse H.","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-9587","authenticated-orcid":false,"given":"Andrea","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"59560_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1448","volume":"6","author":"SB Sospeter","year":"2023","unstructured":"Sospeter, S. B. et al. Ebola outbreak in DRC and Uganda; an East African public health concern. Health Sci. Rep. 6, e1448 (2023).","journal-title":"Health Sci. Rep."},{"key":"59560_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/femsre\/fuw010","volume":"40","author":"R Burk","year":"2016","unstructured":"Burk, R. et al. Neglected filoviruses. FEMS Microbiol Rev. 40, 494\u2013519 (2016).","journal-title":"FEMS Microbiol Rev."},{"key":"59560_CR3","unstructured":"WHO. Ebola Virus Disease in Uganda SitRep - 93, https:\/\/www.afro.who.int\/countries\/uganda\/publication\/ebola-virus-disease-uganda-sitrep-93 (2023)."},{"key":"59560_CR4","doi-asserted-by":"publisher","unstructured":"Kyobe Bosa, H. et al. Sudan Ebola virus disease outbreak in Uganda - a role for cryptic transmission? Nat. Med. https:\/\/doi.org\/10.1038\/d41591-025-00012-0 (2025).","DOI":"10.1038\/d41591-025-00012-0"},{"key":"59560_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","volume":"181","author":"E Ollmann Saphire","year":"2020","unstructured":"Ollmann Saphire, E. A vaccine against Ebola virus. Cell 181, 6 (2020).","journal-title":"Cell"},{"key":"59560_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06360-3","volume":"23","author":"E Karita","year":"2022","unstructured":"Karita, E. et al. Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial. Trials 23, 513 (2022).","journal-title":"Trials"},{"key":"59560_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00685-z","volume":"8","author":"W Cao","year":"2023","unstructured":"Cao, W. et al. The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs. NPJ Vaccines 8, 91 (2023).","journal-title":"NPJ Vaccines"},{"key":"59560_CR8","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1128\/JVI.00561-09","volume":"83","author":"TW Geisbert","year":"2009","unstructured":"Geisbert, T. W. et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 83, 7296\u20137304 (2009).","journal-title":"J. Virol."},{"key":"59560_CR9","unstructured":"WHO. Sudan Ebolavirus Vaccine Tracker - List of vaccine candidates in research & development, https:\/\/www.who.int\/publications\/m\/item\/sudan-virus-vaccine-tracker---list-of-vaccine-candidates-in-research---development (2023)."},{"key":"59560_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117\u2013129 (2021).","journal-title":"Gene Ther."},{"key":"59560_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446\u2013455 (2018).","journal-title":"Mol. Ther."},{"key":"59560_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47905-1","volume":"15","author":"NT Ho","year":"2024","unstructured":"Ho, N. T. et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat. Commun. 15, 4081 (2024).","journal-title":"Nat. Commun."},{"key":"59560_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda, Y. et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2. Lancet Infect. Dis. 24, 341\u2013343 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"59560_CR14","doi-asserted-by":"publisher","unstructured":"Silva-Pilipich, N., Beloki, U., Salaberry, L. & Smerdou, C. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines https:\/\/doi.org\/10.3390\/vaccines12030318 (2024).","DOI":"10.3390\/vaccines12030318"},{"key":"59560_CR15","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.ymthe.2023.06.017","volume":"31","author":"T Kimura","year":"2023","unstructured":"Kimura, T. et al. A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation. Mol. Ther. 31, 2360\u20132375 (2023).","journal-title":"Mol. Ther."},{"key":"59560_CR16","doi-asserted-by":"publisher","unstructured":"Erasmus, J. H. et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abc9396 (2020).","DOI":"10.1126\/scitranslmed.abc9396"},{"key":"59560_CR17","doi-asserted-by":"publisher","unstructured":"Hawman, D. W. et al. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. eLife https:\/\/doi.org\/10.7554\/eLife.75537 (2022).","DOI":"10.7554\/eLife.75537"},{"key":"59560_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104196","volume":"83","author":"DW Hawman","year":"2022","unstructured":"Hawman, D. W. et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naive hamsters compared to ancestral vaccine. EBioMedicine 83, 104196 (2022).","journal-title":"EBioMedicine"},{"key":"59560_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104188","volume":"82","author":"SS Leventhal","year":"2022","unstructured":"Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. EBioMedicine 82, 104188 (2022).","journal-title":"EBioMedicine"},{"key":"59560_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","volume":"30","author":"A Saraf","year":"2024","unstructured":"Saraf, A. et al. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial. Nat. Med 30, 1363\u20131372 (2024).","journal-title":"Nat. Med"},{"key":"59560_CR21","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1128\/JVI.03361-12","volume":"87","author":"AS Herbert","year":"2013","unstructured":"Herbert, A. S. et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J. Virol. 87, 4952\u20134964 (2013).","journal-title":"J. Virol."},{"key":"59560_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02494-24","volume":"15","author":"TAH Hick","year":"2024","unstructured":"Hick, T. A. H., Geertsema, C., Nijland, R. & Pijlman, G. P. Packaging of alphavirus-based self-amplifying mRNA yields replication-competent virus through a mechanism of aberrant homologous RNA recombination. mBio 15, e0249424 (2024).","journal-title":"mBio"},{"key":"59560_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00887-z","volume":"9","author":"DW Hawman","year":"2024","unstructured":"Hawman, D. W. et al. A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever. NPJ Vaccines 9, 86 (2024).","journal-title":"NPJ Vaccines"},{"key":"59560_CR24","unstructured":"University of Texas Medical Branch News. UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology. https:\/\/www.utmb.edu\/utmb\/news-article\/utmb-news\/2022\/11\/30\/utmb-awarded-funding-from-the-u.s.-government-to-develop-sarna-vaccine-technology (2022)."},{"key":"59560_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41541-024-00985-y","volume":"9","author":"A Marzi","year":"2024","unstructured":"Marzi, A. & Feldmann, H. Filovirus vaccines as a response paradigm for emerging infectious diseases. NPJ Vaccines 9, 186 (2024).","journal-title":"NPJ Vaccines"},{"key":"59560_CR26","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","volume":"4","author":"A Marzi","year":"2023","unstructured":"Marzi, A. et al. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques. Lancet Microbe 4, e171\u2013e178 (2023).","journal-title":"Lancet Microbe"},{"key":"59560_CR27","doi-asserted-by":"publisher","unstructured":"Parish, L. A., Stavale, E. J., Houchens, C. R. & Wolfe, D. N. Developing vaccines to improve preparedness for filovirus outbreaks: the perspective of the USA Biomedical Advanced Research and Development Authority (BARDA). Vaccines https:\/\/doi.org\/10.3390\/vaccines11061120 (2023).","DOI":"10.3390\/vaccines11061120"},{"key":"59560_CR28","unstructured":"United States Library of Medicine. Sudan virus https:\/\/classic.clinicaltrials.gov\/ct2\/results?cond=Sudan+virus&term=&cntry=&state=&city=&dist= (2023)."},{"key":"59560_CR29","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","volume":"23","author":"B Mwesigwa","year":"2023","unstructured":"Mwesigwa, B. et al. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. Lancet Infect. Dis. 23, 1408\u20131417 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"59560_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1128\/JVI.02331-15","volume":"90","author":"G Wong","year":"2016","unstructured":"Wong, G. et al. Development and characterization of a guinea pig-adapted Sudan virus. J. Virol. 90, 392\u2013399 (2016).","journal-title":"J. Virol."},{"key":"59560_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.aab3920","volume":"349","author":"A Marzi","year":"2015","unstructured":"Marzi, A. et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain. Science 349, 739\u2013742 (2015).","journal-title":"Science"},{"key":"59560_CR32","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1128\/JVI.00959-06","volume":"80","author":"KM Daddario-DiCaprio","year":"2006","unstructured":"Daddario-DiCaprio, K. M. et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80, 9659\u20139666 (2006).","journal-title":"J. Virol."},{"key":"59560_CR33","doi-asserted-by":"publisher","unstructured":"Bukreyev, A. et al. Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2765936\/v1 (2023).","DOI":"10.21203\/rs.3.rs-2765936\/v1"},{"key":"59560_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857481","volume":"13","author":"J Mellors","year":"2022","unstructured":"Mellors, J. et al. Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: implications for protection and pathogenesis. Front. Immunol. 13, 857481 (2022).","journal-title":"Front. Immunol."},{"key":"59560_CR35","doi-asserted-by":"publisher","first-page":"e0008602","DOI":"10.1371\/journal.pntd.0008602","volume":"14","author":"W Furuyama","year":"2020","unstructured":"Furuyama, W., Nanbo, A., Maruyama, J., Marzi, A. & Takada, A. A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection. PLoS Negl. Trop. Dis. 14, e0008602 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"Suppl. 2","key":"59560_CR36","doi-asserted-by":"publisher","first-page":"S400","DOI":"10.1086\/520587","volume":"196","author":"PB Jahrling","year":"2007","unstructured":"Jahrling, P. B., Geisbert, J. B., Swearengen, J. R., Larsen, T. & Geisbert, T. W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196(Suppl. 2), S400\u2013S403 (2007).","journal-title":"J. Infect. Dis."},{"key":"59560_CR37","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1371\/journal.ppat.0030009","volume":"3","author":"WB Oswald","year":"2007","unstructured":"Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).","journal-title":"PLoS Pathog."},{"key":"59560_CR38","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.celrep.2018.07.035","volume":"24","author":"NA Kuzmina","year":"2018","unstructured":"Kuzmina, N. A. et al. Antibody-dependent enhancement of Ebola virus infection by human antibodies isolated from survivors. Cell Rep. 24, 1802\u20131815.e1805 (2018).","journal-title":"Cell Rep."},{"key":"59560_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2021.03.009","volume":"54","author":"BM Gunn","year":"2021","unstructured":"Gunn, B. M. et al. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity 54, 815\u2013828.e815 (2021).","journal-title":"Immunity"},{"key":"59560_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682120","volume":"12","author":"D Paquin-Proulx","year":"2021","unstructured":"Paquin-Proulx, D. et al. Associations between antibody Fc-mediated effector functions and long-term sequelae in Ebola virus survivors. Front. Immunol. 12, 682120 (2021).","journal-title":"Front. Immunol."},{"key":"59560_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"issue":"Suppl. 3","key":"59560_CR42","doi-asserted-by":"publisher","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","volume":"204","author":"A Marzi","year":"2011","unstructured":"Marzi, A. et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 204(Suppl. 3), S1066\u2013S1074 (2011).","journal-title":"J. Infect. Dis."},{"key":"59560_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ilar\/ilab011","volume":"61","author":"Z Schiffman","year":"2022","unstructured":"Schiffman, Z. et al. The ferret as a model for filovirus pathogenesis and countermeasure evaluation. ILAR J. 61, 62\u201371 (2022).","journal-title":"ILAR J."},{"key":"59560_CR44","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"J. Epidemiol."},{"key":"59560_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3389\/fimmu.2019.01025","volume":"10","author":"GK Lewis","year":"2019","unstructured":"Lewis, G. K. et al. Knowns and unknowns of assaying antibody-dependent cell-mediated cytotoxicity against HIV-1. Front. Immunol. 10, 1025 (2019).","journal-title":"Front. Immunol."},{"key":"59560_CR46","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.4269\/ajtmh.18-0937","volume":"100","author":"F Feldmann","year":"2019","unstructured":"Feldmann, F., Shupert, W. L., Haddock, E., Twardoski, B. & Feldmann, H. Gamma irradiation as an effective method for inactivation of emerging viral pathogens. Am. J. Trop. Med. Hyg. 100, 1275\u20131277 (2019).","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59560-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:53:36Z","timestamp":1746536016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59560-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59560"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59560-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.L.W., E.T.S., K.H., T.H., A.P.K. and J.H.E. receive a salary and have equity interests in HDT Bio. J.H.E. is an inventor on US patent application no. 62\/993,307 \u201cCompositions and methods for delivery of RNA\u201d pertaining to the LION formulation for vaccine development. There are no restrictions on the publication of research data. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4199"}}